A research team from the Department of Pathology, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with the HKU State Key Laboratory of Liver Research, has found that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction-associated fatty liver disease (MAFLD), demonstrates benefits beyond reducing liver fat and fibrosis. The study, published in Hepatology, shows that the drug also has the potential to prevent and suppress liver cancer caused by fatty liver disease.
This article was originally published on MedicalXpress.com
